MarioAlfredoEisenbergerMD

PubMed

• 1 citations
  Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled Trial.
  Catherine H Marshall, Benjamin A Teply, Jiayun Lu, Lia Oliveira, Hao Wang
  JAMA Oncology. 2024-10-01
• 1 citations
  High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial.
  Channing J Paller, Marianna L Zahurak, Adel Mandl, Nicole A Metri, Aliya Lalji
  Cancer Research Communications. 2024-08-01
• 4 citations
  Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial.
  Mark C Markowski, Mary-Ellen Taplin, Rahul Aggarwal, Laura A Sena, Hao Wang
  Nature Communications. 2024-01-02

Journal Articles

• Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer  
  Emmanuel S Antonarakis, Ashley E Ross, Michael A Gorin, Samuel R Denmeade, Channing J Paller, Kenneth J Pienta, Mario A Eisenberger, JAMA Oncology
• Original Contribution TP53 Missense Mutation Is Associated with Increased Tumor-Infiltrating T-cells in Primary Prostate Cancer☆  
  Tamara L Lotan, Mario Eisenberger, Harsimar B Kaur, Scott A Tomlins, Edward M Schaeffer, ScienceDirect
• Androgen Receptor-Targeted Treatments for Prostate Cancer: 35 Years Progress with Antiandrogens  
  Crawford ED, Schellhammer PF, McLeod DG, Moul JW, Higano CS, Shore N, Denis L, Iversen P, Eisenberger MA, Labrie F, The Journal of Urology, 1/1/2018
• Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study  
  Teply BA, Wang H, Luber B, Sullivan R, Rifkind I, Bruns A, Spitz A, DeCarli M, Sinibaldi V, Pratz CF, Lu C, Silberstein JL, Luo J, Schweizer MT, Drake CG, Carducci MA,..., Lancet Oncology, 1/1/2018
• Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15...  
  Gravis G, Boher JM, Chen YH, Liu G, Fizazi K, Carducci MA, Oudard S, Joly F, Jarrard DM, Soulie M, Eisenberger MJ, Habibian M, Dreicer R, Garcia JA, Hussain MHM, Kohli..., European Urology, 1/1/2018
• Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial  
  Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney..., Journal of Clinical Oncology, 1/1/2018
• Expression of AR-V7 and ARv567es in circulating tumor cells correlates with outcomes to taxane therapy in men with metastatic prostate cancer treated in TAXYNERGY  
  Tagawa ST, Antonarakis ES, Gjyrezi A, Galletti G, Kim S, Worroll D, Stewart J, Zaher A, Szatrowski TP, Ballman KV, Kita K, Tasaki S, Bai Y, Portella L, Kirby BJ, Saad ..., Clinical Cancer Research, 1/1/2018
• Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial  
  Paller CJ, Zhou XC, Heath EI, Taplin ME, Mayer T, Stein MN, Bubley GJ, Pili R, Hudson T, Kakarla R, Abbas MM, Anders NM, Dowling D, King S, Bruns AB, Wagner WD, Drake ..., Clinical Cancer Research, 1/1/2018
• Reply to M Horiguchi et al  
  Eisenberger MA, Zhang W, Shun Z, de Bono J, Journal of Clinical Oncology, 1/1/2018
• Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment  
  Moyer CL, Phillips R, Deek MP, Radwan N, Ross AE, Antonarakis ES, Reyes D, Wright J, Terezakis SA, Song DY, DeVille C, Walsh PC, DeWeese TL, Carducci M, Schaeffer EM, ..., World Journal of Urology, 1/1/2018
• Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer  
  Tosco L, Briganti A, Damico AV, Eastham J, Eisenberger M, Gleave M, Haustermans K, Logothetis CJ, Saad F, Sweeney C, Taplin ME, Fizazi K, European Urology, 1/1/2018
• Screening and baseline analysis of circulating tumor cell (CTC) counts and androgen receptor (AR) localization with clinical characteristics of men with metastatic cas...  
  Tagawa, S.T, Galetti G, Antonarakis ES, Tasaki S, Gjyrezi A, Worroll, D, Portella L, Kirby B, Stewart A, Zaher A, Saad F, Vanhuyse M, Suri S, Lannin TB, Gruber C, Prat..., European Journal of Cancer, 1/1/2017
• A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)  
  Radwan N, Phillips R, Ross A, Rowe SP, Gorin MA, Antonarakis ES, Deville C, Greco S, Denmeade S, Paller C, Song DY, Diehn M, Wang H, Carducci M, Pienta KJ, Pomper MG, ..., BMC Cancer, 1/1/2017
• Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treat...  
  Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Zhu Y, Silberstein JL, Taylor MN, Maughan BL, Denmeade SR, Pienta KJ, Paller CJ, Carducci MA, Eisenberger MA, Luo J, Journal of Clinical Oncology, 1/1/2017
• Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Na...  
  Antonarakis ES, Tagawa ST, Galletti G, Worroll D, Ballman K, Vanhuyse M, Sonpavde G, North S, Albany C, Tsao CK, Stewart J, Zaher A, Szatrowski T, Zhou W, Gjyrezi A, T..., Journal of Clinical Oncology, 1/1/2017
• Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone Sensitive Prostate Cancer Treated With Androgen Deprivation With Or Without Docetaxel  
  Harshman LC, Chen YH, Liu G, Carducci MA, Jarrard D, Dreicer R, Hahn N, Garcia JA, Hussain M, Shevrin D, Eisenberger M, Kohli M, Plimack ER, Cooney M, Vogelzang NJ, Pi..., Journal of Clinical Oncology, 1/1/2017
• Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer  
  Bruce Montgomery, Mario A. Eisenberger, Matthew B. Rettig, Franklin Chu, Roberto Pili, Joseph J. Stephenson, Nicholas J. Vogelzang, Alan J. Koletsky, Luke T. Nordquist..., Cancer Res, 1/15/2016
• Use and Outcome of Sunitinib Treatment in Patients With Diabetes and Metastatic Renal Cell Carcinoma  
  Daniel Keizman, �Maya Ish-Shalom, �Avishay Sella, �Maya Gottfried, �Natalie Maimon, Avivit Peer, Hans Hammers, Mario A. Eisenberger, Victoria Sinibaldi, Victoria Neima..., Clinical Genitourinary Cancer, 1/1/2016
• Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer  
  Halabi S, �Kelly W.K., �Ma H, �Zhou H, �Solomon N.C., �Fizazi K, �Tangen C.M., Rosenthal M, Petrylak D.P., Hussain M, Vogelzang N.J., Thompson I.N., Chi K.N., De Bono ..., Journal of Clinical Oncology, 1/1/2016
• Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?  
  Keizman D, Rouvinov K, Sella A, Gottfried N, Maimon N, Kim J.J., Eisenberger M.A., Sinibaldi V, Peer A, Carducci M.A., Mermershtain W, Leibowitz-Amit R, Weitzen R, Ber..., Cancer Research and Treatment: Official Journal of Korean Cancer Association, 1/1/2016
• Potential Predictive Role for Prostate-specific Antigen Changes at 4 Weeks?  
  Maughan B.L., �Eisenberger M.A., European Urology, 1/1/2016
• Androgen Receptor Modulation Optimized for Response (ARMOR) phase i and II studies: Galeterone for the treatment of castration-resistant prostate cancer  
  Montgomery B, Eisenberger M.A., Rettig M.B., Chu F, Pili R, Stephenson J.J, Vogelzang N.J, Koletsky A.J., Nordquist L.T., Edenfield W.J., Mamlouk K, Ferrante K.J., Tap..., Clinical Cancer Research, 1/1/2016
• Intermittent Androgen Deprivation in Prostate Cancer: Are we ready to quit?  
  Park, JC, Eisenberger MA, J Clin Oncol, 1/1/2016
• Comparison of Prostate- Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naive and Castration-Resistant Met...  
  Rowe S.P., Macura K.J., Ciarallo A, Mena E, Blackford A, Nadal R, Antonarakis E.S., Eisenberger M.A., Carducci M.A., Ross A.E., Kantoff P.W., Holt D.P., Dannals R.F., ..., Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine, 1/1/2016
• PSMA-Based (18F)DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer  
  Rowe S.P., Macura K.J., Mena E, Blackford A.L, Nadal R, Antonarakis E.S., Eisenberger M.A., Carducci M.A., Fan H, Dannals R.F., Chen Y, Mease R.C., Szabo Z, Pomper M.G..., Molecular Imaging and Biology, 1/1/2016
• Join now to see all

Books/Book Chapters

• Current Clinical Oncology: Prostate Cancer: Signaling Networks, Genetics and New Treatment Strategies 
  Chapter: The Current Knowledge of Hormonal Therapy in the Treatment of Prostate Cancer 
  Eisenberger MA2007
• Prostate Cancer 
  Chapter: Committee 13, new therapeutic targets and treatments for metastatic prostate cancer. 
  Nelson, W.G., Saad, F., Debruyne, F.M.J., Eisenberger, M.A., Fourcade, R., Frenkel, E.P., Kantoff, P.W., Kumon, H., Nasu, Y., Oudard, S., and Wirth, M.Editors: McConnell, J., Denis, L., Akaza, H., Khoury, S., and Schalken, J..Health Publications, Paris, France2006
• Prostate Cancer, Principles & Practice 
  Chapter: Controversies in hormone treatment for prostate cancer. 
  Eisenberger MANartub Dybutz Ktd (Taylor & Francis Group)2005
• Report to the Nation on Prostate Cancer 
  Chapter: Therapeutic Strategies for Patients With a Rising PSA: A Case-Based Approach. 
  Page 85 - 92D'Amico AV, Eisenberger MA, Partin AW, Pienta KJ2004
• Clinical Oncology 
  Chapter: Prostate Cancer. 
  Page 2085 - 2148Eisenberger MAEditors: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG.Edition 3rd,2004
• Renal, Bladder and Prostate Cancer An Update 
  Chapter: Non-Endocrine Systemic Approaches For Prostate Cancer: Current Status And Future Directions. 
  Page 219 - 228Eisenberger MAEditors: Fritz Schroder.Parthenon Publishing2001
• The Guide to Living with Bladder Cancer 
  Schoenberg, MP, Bluemke DA, Carducci MA, DeMarzo AM, DeWeese TL, Eisenberger MA, Mandavili S, Rosenthal DL, Sinibaldi VJW, Walker JM, Willmann J, and Wills Marcia2000
• Prostate Cancer 
  Chapter: Treatment of Hormone Resistant Disease. 
  Page 409 - 435Rubben H, Schmidt J.D., Eisenberger M, Lluch I, Pienta K.J., and Logothetis CEditors: G. Murphy, S. Khoury, A. Partin and L. Denis.2000
• Renal, Bladder and Prostate Cancer An Update 
  Chapter: New Approaches To Drug Development in Prostate Cancer. 
  Page 211 - 218Eisenberger MAEditors: Karl Kurth, Gerald Mickisch and Fritz Schroder.Parthenon Publishing (PACIO V - 1998)1999
• Campbell's Urology, Study Guide 
  Chapter: Chemotherapy for Hormone-Resistant Prostate Cancer. 
  Page 2645 - 2658Eisenberger MAEditors: Walsh PC, Retik AB, Vaughan ED, Wein AJ.Saunders1998
• Proceedings of the First International Consultation on Prostate Cancer 
  Chapter: Secondary hormonal treatment. 
  Page 305 - 324Mahler C, Akaza H, Boccardo F, Coulange C, DiSilverio F, Eisenberger M, Jakse G, Tunn U, Varkarakis M, Verhelst JEditors: Murphy G, Denis L, Chatelain C, Griffiths K, Khoury S, Cockett.Scientific Communications International1997
• Campbell's Urology 
  Chapter: Chemotherapy for hormone-resistant prostate cancer. 
  Page 2645 - 2658Eisenberger MEditors: Walsh, Retik, Vaughn, Wein.SaundersEdition 7th,1997
• Comprehensive Text Book of Genito-Urinary Oncology 
  Chapter: Suramin in advanced prostate cancer. 
  Carducci M, Eisenberger M, Kobayashi K, Reyno L, and Egorin M1996
• Current Genito Urinary Cancer Surgery 
  Chapter: Chemotherapy for cancer of the prostate. 
  Page 667 - 677Eisenberger MEditors: Crawford.Edition 2nd,1996
• The Chemotherapy Source Book 
  Chapter: Hormonal agents for the treatment of cancer. 
  Page 459 - 476Aisner J, Fram R, Eisenberger M, and Fontana JEditors: Michael C. Perry.Williams & Wilkins, Baltimore, MDEdition 2nd,1996
• Oncology - Current Practice of Medicine 
  Chapter: Genito-urinary malignancies. 
  Eisenberger MEditors: Ettinger D..1996
• Gonodotropin Hormone Releasing Hormone Analogues, Infertility and Reproductive Medicine Clinics of North America 
  Chapter: Use of GNRH analogues in oncology: prostate and breast cancer. 
  Page 171 - 188Eisenberger M, and Parnes HEditors: M.L. Polan, M.R. Henzl.1993
• Cancer of the Prostate 
  Chapter: Chemotherapy and Palliation in Prostate Cancer. 
  Page 369 - 398Eisenberger MEditors: Crawford ED, Das S.Marcell Dekker Inc.1993
• The Chemotherapy Source Book 
  Chapter: Hormonal Agents. Section Two: Chemotherapy Drugs. 
  Page 413 - 429Aisner J, Eisenberger M, and Fontanta JEditors: M.J. Perry.Williams & Wilkins1992
• Advances En Cancer De Cabeza Y Cuello 
  Chapter: Quimiotherapia en el carcinoma epidermoids de cabeza y cuello. 
  Page 205 - 214Belani C, Eisenberger MEditors: Gonzales Baron.SMAR, Madrid, Spain1992
• The Uriologic Clinics of North America 
  Chapter: Chemotherapy for Carcinomas of the Penis and Urethra. 
  Page 333 - 338Eisenbeger MSEditors: Crawford ED, Das S.W.B. Saunders Company1992
• Avances en Cancer de Cabeza Y Cuello 
  Chapter: Carcinoma epdermoide de cabeza e cuello locamente avanzado e irresecable: Tratamintos combinados con quimiotherapia y radioterpia conventional sincronicas. 
  Page 183 - 188Belani C, and Eisenberger MEditors: Gonzales Baron.SMAR, Madrid, Spain1992
• Monographs of the European School of Oncology on The Medical Management of Prostate Cancer 
  Chapter: Chemotherapy for advanced prostate cancer. 
  Page 75 - 87Eisenberger MEditors: L. Denis.Springer-Verlag Publishers, NY1991
• Cancer: A Technical Monograph 
  Chapter: Male genital cancers: prostate and testicle. 
  Page 29 - 35Eisenberger MEditors: M. Mitchell.National Labs1991
• Treatment of Prostatic Cancer: Facts and Controversies 
  Chapter: Chemotherapy for endocrine resistant cancer of the prostate. 
  Page 155 - 164Eisenberger MEditors: F. Schroder.Wiley-Liss1990
• Join now to see all

Abstracts/Posters

• Characteristics and outcome of octogenarian versus young patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) treated with ketoconazole.
  V.J. Sinibaldi, M. Dadon-Nachum, M. Gottfried, N. Maimon, Z. Dovrish, A. Peer, A. Neumann, A. Sella, S. Kovel, M.A. Carducci, M.A. Eisenberger, D. Keizman, Genitourinary Cancers Symposium, 1/1/2014
• A pilot study of supraphysiologic testosterone (T) and oral etoposide (E) in men with castrate-resistant prostate cancer (CRPC).
  M.T. Schweizer, E.S. Antonarakis, H. Wang, A.N. Spitz, H.Cao, A. Pacheo, M.A. Eisenberger, M.A. Carducci, S.R. Denmeade, Genitourinary Cancers Symposium, 1/1/2014
• A phase I trial of muscadine grape skin in men with biochemically recurrent prostate cancer.
  C.J. Paller, M.A. Rudek, E.S. Antonarakis, M.A. Eisenberger, H.J. Hammers, X.C. Zhou, D. Dowling, S. King, S. Hudock, S.R. Denmeade, W.D. Wagner, G.L. Rosner, T. Hudso..., Genitourinary Cancers Symposium, 1/1/2014
• Potential impact of prior high-dose IL-2 on the outcomes of sunitinib (Su) treatment (tx) in patients (pts) with metastatic renal cell carcinoma (mRCC).
  E. Rosenbaum, M. Gottfried, H.J. Hammers, M.A. Eisenberger, M.A. Carducci, V.J. Sinibaldi, V. Neiman, D. Sarid, E. Gez, H. Hayat, A. Peer, A. Sella, W. Mermershtain, K..., Genitourinary Cancers Symposium, 1/1/2014
• Patients with metastatic papillary renal cell carcinoma (RCC) who may benefit from sunitinib therapy (tx): Results from an international metastatic RCC database.
  D. Kejzman, M. Gottfried, N. Maimon, H.J. Hammers, M.A. Eisenberger, M.A. Carducci, V.J. Sinibaldi, V. Neiman, E. Rosenbaum, D. Sarid, E. Gez, A. Peer, A. Sella, W. Me..., Genitourinary Cancers Symposium, 1/1/2014
• Clinicopathologic factors associated with the development of sunitinib induced hypertension (HTN) in patients (pts) with metastatic renal cell carcinoma (mRCC).
  V. Neiman, M. Gottfried, H.J. Hammers, M.A. Eisenberger, M.A. Carducci, V.J. Sinibaldi, E. Rosenbuam, D. Sarid, E. Gez, A. Peer, A. Neumann, S. Kovel, A. Sella, W. Mer..., Genitourinary Cancers Symposium, 1/1/2014
• The effect of prior abiraterone (Abi) treatment on subsequent response to docetaxel in men with castrate resistant prostate cancer (CRPC).
  M.T. Schweizer, X.C. Zhou, H. Wang, S. Bassi, M.A. Carducci, M.A. Eisenberger. E.S. Antonarakis, Genitourinary Cancers Symposium, 1/1/2014
• The effect of change in PSA velocity on overall survival (OS) in men with biochemically recurrent prostate cancer (BRPC) treated with nonhormonal agents: Combined anal...
  D.L. Suzman, M. Zahurak, M.A. Carducci, M.A. Eisenberger, E.S. Antonarakis, Genitourinary Cancers Symposium, 1/1/2014
• Clinical activity of enzalutamide pre- and post-docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC).
  R. Nadal, Z. Zhang, H. Raheja, M.A. Eisenberger, E.S. Antonarakis, Genitourinary Cancers Symposium, 1/1/2014
• Are there geographic differences in the outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (su)?
  D. Keizman, M.I. Shalom, N. Maimon, M. Gottfried, R. Pili, H.J. Hammers, M.A. Eisenberger, V.J. Sinibaldi, B. Boursi, R. Weitzen, H. Hayat, A. Peer, A. Neumann, et al, Genitourinary Cancers Symposium, 1/1/2013
• Is there a "trial effect" on outcome of patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib?
  D. Keizman, M.I. Shalom, N. Maimon, M. Gottfried, R. Pili, H.J. Hammers, M.A. Eisenberger, V.J. Sinibaldi, B. Boursi, R. Weitzen, H. Hayat, A. Peer, et al, Genitourinary Cancers Symposium, 1/1/2013
• The initial biopsy Gleason score as a predictive marker for docetaxel survival benefit in patients with prostate cancer: Data from the TAX 327 study.
  R. Soest, E d Morr�e, L. Shen, I. Tannock, M.A. Eisenberger, R. DeWit, Genitourinary Cancers Symposium, 1/1/2013
• Influence of concurrent medications on PSA doubling time (PSADT) in patients (pts) with nonmetastatic biochemically relapsed prostate cancer (BRPC M0) after local ther...
  D. Keizman, M.I. Shalom, N. Maimon, M. Gotttfried, K. Roubinov, R. Pili, V.J. Sinibaldi, H.J. Hammers, M.A. Carducci, M.A. Eisenberger, Genitourinary Cancers Symposium, 1/1/2013
• Comparison of abiraterone acetate (Abi) versus ketoconazole (Keto) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to docetax...
  A. Peer, M. Ish-Shalom, N. Maimon, M. Gottfried, B. Boursi, R. Leibowitz-Amit, R. Berger, A. Neumann, S. Kovel, A. Sella, R. Pili, H.J. Hammers, V.J. Sinibaldi, M.A. C..., Genitourinary Cancers Symposium, 1/1/2013
• Association of metastasis-free survival (MFS) with overall survival (OS) in men with PSA-recurrent prostate cancer treated with deferred androgen-deprivation therapy.
  M.T. Schweizer, X.C. Zhou, H. Wang, T. Yang, F. Shaukat, M.A. Eisenberger, E. S. Antonarakis, Genitourinary Cancers Symposium, 1/1/2013
• PROSELICA study update: Comparison of two doses of cabazitaxel (Cbz) plus prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)...
  M.A. Eisenberger, A.C. Hardy-Bessard, D. Ford, L. Mourey, P. Parente, P. Mainwaring, S. Ng, B. Alekseev, V. Matveev, J. Carles, J. Shapiro, I. Latozeff, I. Bodrogi, C...., ASCO (American Society of Clinical Oncology) Annual Meeting, 1/1/2013
• Are there geographic differences in the outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (su)?
  D. Keizman, M. Ish-Shalom, N. Maimon, M. Gottfried, R. Pili, H.J. Hammers, M.A. Eisenberger, V.J. Sinibaldi, B. Boursi, R. Weitzen, H. Hayat, A. Peer, A. Neumann, S. K..., ASCO (American Society of Clinical Oncology) Annual Meeting, 1/1/2013
• Prospective evaluation of testosterone (T) recovery and PSA relapse following 18 months of androgen deprivation (ADT) after prostatectomy (RP): Results from the TAX-35...
  M.T. Schweizer, P. Huang, C.N. Sternberg, R. DeWit, E. B. Ecstein-Fraisse, M.W. Kattan, A. S. Kibel, M.A. Eisenberger, ASCO (American Society of Clinical Oncology) Annual Meeting, 1/1/2013
• Comparison between the outcome of metastatic RCC patients treated with sunitinib as part of clinical trials and matched nonparticipants receiving sutent as standard th...
  R. Berger, M. Ish-Shalom, N. Maimon, M. Gottfried, R. Pili, H.J. Hammers, M.A. Eisenberger, V.J. Sinibaldi, B. Boursi, R. Weitzen, H. Hayat, A. Peer, A. Neumann, S. Ko..., ASCO (American Society of Clinical Oncology) Annual Meeting, 1/1/2013
• TAXYNERGY (NCT01718353): A randomized phase II trial examining an early switch from first-line docetaxel to cabazitaxel, or cabazitaxel to docetaxel, in men with metas...
  E.S. Antonarakis, P. Giannakakou, B. J. Kirby, L.V. Nicacio, M.A. Eisenberger, D.M. Nanus, S. T. Tagawa, ASCO (American Society of Clinical Oncology) Annual Meeting, 1/1/2013
• Influence of risk factors for renal cell carcinoma (RCC) on outcome of patients (pts) with metastatic disease treated with sunitinib.
  D. Keizman, M. Ish-Shalom, D. Taskey, R. Pili, H-J. Hammers, M.A. Eisenberger, B. Boursi, et.al., ASCO (American Society of Clinical Oncology) Genitourinary Cancers Symposium, 1/1/2012
• Effect of bisphosphonates (Bis) combined with sunitinib (Su) on the response rate (RR), progression-free survival (PFS), and overall survival (OS) of patients (pts) wi...
  D. Keizman, M. Ish-Shalom, D. Taskey, R. Pili, HJ. Hammers, M.A. Eisenberger, B. Boursi, R. Berger, N. Maimon, M. Gottfried, H. Hayat, A. Peer, S. Kovel, A. Sella, M.A..., ASCO (American Society of Clinical Oncology) Genitourinary Cancers Symposium, 1/1/2012
• Pretreatment (pre-tx) neutrophil to lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with ketoconazole (keto): ...
  D. Keizman, M. Ish-Shalom, N. Maimon, M. Gottfried, M.A. Carducci, M.A. Eisenberger, A. Sella, ASCO (American Society of Clinical Oncology) Genitourinary Cancers Symposium, 1/1/2012
• Overall survival of men with metastatic castration-resistant prostate cancer (mCRPC) receiving first-line docetaxel-containing chemotherapy according to their particip...
  J. Goyal, PH. Huang, P. Tyagi, D. Oh, M.A. Cardduci, M.A. Eisenberger, E.S. Antonarakis, ASCO (American Society of Clinical Oncology) Genitourinary Cancers Symposium, 1/1/2012
• Pretreatment (pre-tx) neutrophil to lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with ketoconazole (keto): ...
  A. Sella, M. Ish-Shalom, N. Maimon, M. Gottfried, A. Neumann, A. Peer, E. Rosembaum, S. Kovel, V.J. Sinibaldi, HJ. Hammers, M.A. Carducci, M.A. Eisenberger, D. Keizman, ASCO (American Society of Clinical Oncology) Annual Meeting, 1/1/2012
• Join now to see all

Lectures

• Advances in Hormonal therapy for prostate cancer and optimal timing for androgen deprivation. 
  1/1/2016
• Selected Aspects in the management and treatment of Relapsed Prostate Cancer. 
  University of Maryland Cancer Center - 1/1/2016
• Biomarkers in Prostate Cancer 
  Boston, MA - 1/1/2015
• Treatment for urothelial and prostate cancer treatment. 
  1/1/2014
• Cytotoxic Chemotherapy and Immunotherapy for Prostate Cancer. 
  Dusseldorf, Germany - 1/1/2013
• Systemic approaches for metastatic prostate cancer. 
  Milan, Italy - 1/1/2013
• Systemic Treatments for Metastatic Castration Resistant Prostate Cancer- Presentation of findings and recommendations to the Society of International Urology on behalf... 
  Berlin, Germany - 1/1/2011
• Current Concepts in systemic treatments for prostate cancer. 
  Stockholm, Sweden - 1/1/2009
• New Drug Development Strategies for Prostate cancer. 
  Barcelona, Spain - 1/1/2008
• "Prostate Cancer in the 21st century" 
  Paris, France - 1/1/2006
• Management of Biochemically Relapsed Prostate cancer. 
  San Francisco, CA - 1/1/2006
• Bone targeted treatment for prostate cancer. 
  Orlando, FL - 1/1/2005
• Role of adjuvant Systemic treatment for high Risk Localized Prostate Cancer. 
  Orlando, FL - 1/1/2005
• Multimodality Treatment for Relapsed Prostate Cancer. 
  Orlando, FL - 1/1/2005
• State of the art approach for the management of patients with biochemically relapsed prostate cancer. 
  New Orleans, LA - 1/1/2004
• New developments in the systemic treatment of prostate cancer - "The Final Results of TAX-327 pivotal study of taxotere for patients with castration resistant prostate... 
  London, England - 1/1/2004
• New developments in Prostate Cancer 
  West Palm Beach, FL - 1/1/2003
• New developments in the treatment of Prostate Cancer. 
  Singapore - 1/1/2001
• "Urological Oncology" 
  Cleveland - 1/1/1998
• Prostate Cancer 
  University of Maryland - 1/1/1998
• Growth Factors Inhibition As A Therapeutic Target For Prostate Cancer Treatment. 
  Bologna, Italy - 1/27/1997
• Chemotherapy for Bladder Cancer. 
  The Hague, The Netherlands - 1/16/1997
• New Advances in Bladder Cancer 
  1/6/1997
• "Renal and Bladder Carcinoma" 
  1/1/1997
• Hormone-Refractory Prostate Cancer. 
  Stockholm, Sweden - 1/1/1996
• Join now to see all

Other

• Chemotherapy for prostate cancer. 
  Eisenberger MA, Plenary Session Debate-European Association of Urology
  Milan, Italy - 1/1/2007
• Therapeutic strategies for patients with a rising PSA: A case-based approach. Report to the Nation on Prostate Cancer 2004. 
  D'Amico AV, Eisenberger MA, Partin AW, Pienta KJ, Prostate Cancer Foundation (pp. 85-92)
  1/1/2004
• Hormonal Therapy for Advanced Prostate Cancer. 
  Eisenberger, M, The Johns Hopkins White Paper Bulletins, Prostate Bulletin Winter Issue (pp. 23-32)
  1/23/2002
• Systemic Treatment of Hormone-Refractory Prostate Cancer, Revista da Sociedade Brasileira de Oncologia. 
  Sinibaldi V and Eisenberger M, SBOC Revista, Vol 2 (pp. 73-87)
  1/1/2000
• Combined Androgen Blockade (CAB) For The Treatment Of Patients With Metastatic Prostatic Cancer: Summary Of 15 Years Of Clinical Research. 
  Laufer M, Carducci M, Blumenstein B, Eisenberger M, AUA Update Series Lesson 29: Volume XVIII
  1/1/1999
• Suramin: Development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate... 
  Jodrell D, Reyno L, Sridhara R. Eisenberger M, Tkaczuk K, Zuhowski E, Sinibaldi V, Novak M, and Egorin M, Classical Papers and Current Comments, Vol 4, No 1 (pp 264-273)
  1/1/1999
• Phase I and Clinical Evaluation of a Pharmacologically Guided Regimen of Suramin in Patients With Hormone-Refractory Prostate Cancer. 
  Eisenberger M, Sinibaldi V, Reyno L, Sridhara R, Jodrell D, Zuhowski E, Tkaczuk K, Lowitt M, Hemady R, Stephen J, VanEcho D and Egorin M, Classic Papers and Current Comments, Vol 2 (No 2)
  1/1/1997
• Active and safe schedule developed for outpatient use of suramin. 
  Eisenberger M, Sinibaldi V, Reyno L, Sridhara R, Jacobs S, and Egorin M, AUA Today
  1/1/1996
• A critical assessment of the role of chemotherapy for endocrine resistant prostatic carcinoma. 
  Eisenberger M, Bezirdjian L, and Kalash S, American Urological Update Series, Lesson 28, Volume VII (pp. 218-224)
  1/1/1988
• Chemotherapy for prostate carcinoma. 
  Eisenberger M, NIH Consensus Development Conference on the Treatment of Prostate Cancer, NCI Monograph (pp. 151-163
  1/1/1988
• Combination chemotherapy with bleomycin and hydroxyurea in the treatment of advanced head and neck cancer. 
  Eisenberger M, O.R.I. Digest
  1/1/1983
• Join now to see all